After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
Dr. Buff Mair is the new CTS Medical Director and replaces Dr. German Leparc who retired at the begi...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols ...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...